Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805961 · ClinicalTrials.gov registry record · Phase 2
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00805961 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 68 participants.
The verdict
NCT00805961, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma. In the first portion of the treatment, bevacizumab will be added to standard concurrent radiation therapy plus temozolomide. After completing radiation therapy, patients will continue treatment with the combination of bevacizumab and everolimus.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- DRUG Everolimus
- RADIATION Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00805961
The ClinicalTrials.gov registry entry for NCT00805961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00805961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00805961 about?
NCT00805961 is a clinical study titled "RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM". In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma. In the first portion of the treatment, bevacizumab will be added to standard concurrent radiation therapy plus temozolomide. After ...
What is the current status of trial NCT00805961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2009-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00805961?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Everolimus (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00805961?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.